Search fresh public links, source activity, and ready-to-use post angles for Biotech Ipo.
Fresh curated links around biotech IPO are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen during the sector’s pandemic peak, according to BioPharma D...
Another biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Therapeutics, a San Diego-based oncology outfit focused on small molecules,...
The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.
Molbio Diagnostics aims to secure ₹200 crore to enhance its capital expenditures through a new issuance of shares. In tandem, the firm intends to reduce promoter stake by generatin...
Two growing biotechs blasted through their IPO expectations Friday, with Blossom Hill Therapeutics and Latigo Biotherapeutics each raising at least 30% more than expected in their...
Attovia Therapeutics, Braveheart Bio and Vogenx have set target ranges for their IPOs, positioning the trio to collectively net more than $500 million from public investors.
Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ultimately be more than $1 billion from public investors.
Biotech IPOs dominate the 2026 US market, overshadowing AI firms like Anthropic. Anthropic's IPO by December 31, 2026 at 63.5% YES. The post Biotech IPOs lead 2026 US market, overs...
The startups are part of a surge of young companies equipped with advanced drug prospects and quickly pivoting to the public markets.
The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other biotech companies that have gone public in 2026.
Molbio, the R&D-backed medical technology company, has strong drivers to sustain growth over the next few years, but valuations are not cheap
The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
Molbio Diagnostics sold its shares in the price band of Rs 768-807 apiece, applied for a minimum of 18 shares and its multiples to raise Rs 940 crore between August 10-12.
BlossomHill Therapeutics plans to raise $111.7 million to fund the clinical journey of its potential challenger to Tagrisso.
A total of 20 IPOs are on investors’ radar next week, including fresh issues and upcoming listings across the mainboard and SME segments. Symbiotec Pharmalab, Tempsens Instruments,...
Issue opens today at Rs 768-807 price band
Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.
In addition to pricing the biggest biotech IPO of the week, Braveheart Bio’s underwriters exercised their option to purchase more shares, boosting the clinical-stage company’s tota...
The de-extinction startup is looking to double or triple its previous valuation, according to the report.
An offer for sale (OFS) of 2.73 crore equity shares will be made by selling shareholders, per the draft red herring prospectus (DRHP) filed Wednesday
The 2026 IPO streak continues as Electra Therapeutics has filed to go public to support its immunology and cancer pipeline.
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.